Bortezomib (Velcade®) 3.5 mg subcutaneous injection
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013000331
English
Authors' recommendations:
Bortezomib (Velcade®) 3.5 mg subcutaneous injection is recommended as an option for use within NHS Wales:
for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for bone marrow transplantation;
in combination with melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/bortezomib%20%28Velcade%29%20FAR%20posted%20to%20website.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Boronic Acids
- Pyrazines
- Multiple Myeloma
- Bortezomib
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.